eQuantX help in building an-evidence based value frameworks and pricing strategies to optimize your product’s market access plans around the world. Our team of market access experts support you in accelerating your product approvals, assessing market risk, establishing appropriate pricing, and increasing speed to market for new and innovative products

SOLUTION

What we offer

eQuantX offers innovative and data-driven solutions for each market access, pricing, and reimbursement engagement from our diverse team of specialists. We develop market access strategies and actionable pricing recommendations, supporting from asset due diligence, through to revenue optimisation along
the entire product life cycle

IMPORTANCE

What is the purpose

Market Access is complex process pharma and biotech companies go through to ensure their innovative products are available in the right market and to the right set of patients. This process includes exercising the right pricing strategy and cost effectiveness across the franchise or portfolio of products, as well as evaluating its potential for getting reimbursements

Ensure Best Access Conditions for New Technology/Product

Preparing a Successful
Commercial Launch

Assessing the Potential for Formulary Inclusion at Local and Regional Level

Enhancing
Payer Engagement

Evaluating Potential for Reimbursement at Local, Regional,and National Level

Communicating
Product Value

Accelerating Patient Access to Innovative Therapies

Optimizing Market
Entry Strategies

Maximizing Product
Affordability and Accessibility

Mitigating
Reimbursement Risks

Enhancing
Competitive Positioning

Facilitating Health Economic
Evaluations

PROCESS

How we do it

ll Our Approach ll

eQuantX provides support to pharma and med device companies in designing a comprehensive and robust market access plans for their assets in the early phase of developments. A market access planning process starts with MA environment assessment, and continues through the product lifecycle

1. Market Access Environment Assessment

This usually performed at the starting of the phase-II studies and focused on the following information to be gathered

Country Healthcare System:- Understanding country-specific healthcare systems and their requirements
Epidemiology Study :- Understanding of disease management and unmet needs
Clinical Evidence Analysis- Understanding of which clinical evidence seems to have mostly impacted in the past
Reimbursement Scenario- Country reimbursement status of current treatments and existing restrictions

2. Designing Preliminary Market Access Plan

The preliminary market access plan is developed based on initial reaction of payers and physicians on the drafted Target Product Profile (TPP). This step plans specific studies and analysis as follows

Disease Background
Payer Insight Generation
Testing and Adapting Target Product Profile
Pricing Study
Payer Engagement Capability Building
Reimbursement Opportunities and Strategy
Clinical/economic Impact Analysis/ Budget Impact Analysis

3. Gap Analysis

After discussion on the given TPP, gap analysis is performed to check the evidence require for desired market access positioning and to achieve ultimate commercial goals. This step has clearly defined objectives and stages to create value through significant development of clinical data and HEOR data/ RWE insights generation.

The output from this Gap Analysis is used into phase III clinical and Real-World Evidence research programs.

4.Designing Final Market Access Plan

Through continuous RWE data development plan and analysis, and once the clinical trial results are available from phase III studies, the Market Access plan can be finalized along with the estimated timelines. A subsequent repositioning/ re-pricing strategies could also be proposed and planned accordingly

Disease Background
Developing Negotiation Pathways etc.
Repositioning Strategy
Re-Pricing Strategy

ll FEATURED ACTIVITIES ll

Effective Interaction with Key Stakeholders’ Groups

Nurturing collaborative relationships and strategic alignment to navigate the complex landscape of reimbursement, pricing, and regulatory dynamics

Evaluating the Cost-effectiveness of Treatment and Products to Support Reimbursement Decisions

Providing a robust economic foundation for healthcare stakeholders to optimize resource allocation and enhance
overall healthcare value

Determining Price and Reimbursement based Clinical
Value and Budget Impact

Aligning with healthcare priorities, cost-effectiveness, and sustainable budget considerations

KOLs and Expert Opinion on Assessment of the Clinical Safety and Efficacy of Innovative Product

Assessing the clinical safety and efficacy of innovative products, ensuring a comprehensive evaluation grounded in the insights of respected authorities in the field

Reviewing Influencing Pricing and Reimbursement Decisions through Payer’s Research

Evaluating payer perspectives, enabling pharmaceutical companies to align their products with payer expectations and enhance market access strategies

Assessing Country Specific Public Hospital Procurement Steps

Comprehensive analysis of the procurement processes unique to each nation’s public healthcare system, facilitating strategic alignment and efficient market access for pharmaceutical products

Market Access Landscape Analysis

Conducting a thorough analysis of the overall market access landscape, including regulatory requirements, competitor strategies, and evolving market trends, to inform a proactive and adaptable market entry approach

Target Product Profile (TPP) Discussion and Conducting a Comprehensive Pricing Study

Guiding the development of a well-defined product profile and strategic pricing model that align with regulatory requirements, market expectations, and value proposition considerations

ll FEATURED PRODUCTS ll

PayerPro360
(Quick Payer Research)

OncoArcT
(Oncology & Rare Disease Insights)

eOptimiZe
(Business Development and Licensing Support)